red; however, in clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of hydrodolasetron (the active metabolite of dolasetron).
Aripiprazole: QT prolongation has occurred during therapeutic use of aripiprazole and following overdose. Dolasetron has been associated with a dose-dependant prolongation in the QT, PR, and QRS intervals on an electrocardiogram. Use of dolasetron injection for the prevention of chemotherapy-induced nausea and vomiting is contraindicated because the risk of QT prolongation is higher with the doses required for this indication; when the injection is used at lower doses (i.e., those approved for post-operative nausea and vomiting) or when the oral formulation is used, the risk of QT prolongation is lower and caution is advised. Aripiprazole should be used cautiously and with close monitoring with dolasetron.
Arsenic Trioxide: Due to a possible risk for QT prolongation and torsade de pointes (TdP) dolasetron and arsenic trioxide should be used together cautiously. Dolasetron has been associated with a dose-dependant prolongation in the QT, PR, and QRS intervals on an electrocardiogram. Use of dolasetron injection for the prevention of chemotherapy-induced nausea and vomiting is contraindicated because the risk of QT prolongation is higher with the doses required for this indication; when the injection is used at lower doses (i.e., those approved for post-operative nausea and vomiting) or when the oral formulation is used, the risk of QT prolongation is lower and caution is advised. If possible, drugs that are known to prolong the QT interval should be discontinued prior to initiating arsenic trioxide therapy. QT prolongation should be expected with the administration of arsenic trioxide. Torsade de pointes (TdP) and complete atrioventricular block have been reported.
Artemether; Lumefantrine: Due to a possible risk for QT prolongation and torsade de pointes (TdP) dolasetron and artemether; lumefantrine should be used together cautiously. Dolasetron has been associated with a dose-dependant prolongation in the QT, PR, and QRS intervals on an electrocardiogram. Use of dolasetron injection for the prevention of chemotherapy-induced nausea and vomiting is contraindicated because the risk of QT prolongation is higher with the doses required for this indication; when the injection is used at lower doses (i.e., those approved for post-operative nausea and vomiting) or when the oral formulation is used, the risk of QT prolongation is lower and caution is advised. Artemether; lumefantrine is an inhibitor and dolasetron is a substrate of the CYP2D6 isoenzyme; therefore, coadministration may lead to increased dolasetron concentrations. Furthermore, although there are no studies examining the effects of artemether; lumefantrine in patients receiving other QT prolonging drugs, coadministration of such drugs may result in additive QT prolongation. Concomitant use of artemether; lumefantrine with drugs that may prolong the QT interval, such as dolasetron, should be avoided. Consider ECG monitoring if dolasetron must be used with or after artemether; lumefantrine treatment.
Asenapine: Due to a possible risk for QT prolongation and torsade de pointes (TdP) dolasetron and asenapine should be used together cautiously. Dolasetron has been associated with a dose-dependant prolongation in the QT, PR, and QRS intervals on an electrocardiogram. Use of dolasetron injection for the pr |
